Literature DB >> 30144567

The possible origin of human adenovirus type 3: Evidence of natural genetic recombination between human and simian adenovirus.

Ji-Wung Han1, Tae-Min La1, Ji-Hoon Kim2, In-Soo Choi1, Chang-Seon Song1, Seung-Yong Park1, Joong-Bok Lee1, Sang-Won Lee3.   

Abstract

We determined a complete genome sequence of the Korean field strain, KUMC-62, of human adenovirus type 3 (HAdV-3) and performed comparative genome analyses. Interestingly HAdV-3 has a distinct genomic sequence for the fiber CDS region on average 62.46% of nucleotide sequence identity to other types of HAdV-B1, while remaining genomic region of HAdV-3 is very similar (on average 95.71% of nucleotide sequence identity) to other types of HAdV-B1. The blast results showed that the fiber CDS region of HAdV-3 exhibited the highest nucleotide sequence identity with that of simian adenovirus type 32 (SAdV-32), except other strains of HAdV-3. In the Simplot analysis, a potential recombination event was detected between HAdV-7 and SAdV-32, which might have created HAdV-3 in the past. These findings suggest that HAdV-3 highly likely was created by a natural inter-species recombination event between human and non-human primate AdVs.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Comparative genome analysis; High-throughput sequencing; Human adenovirus type 3; Recombination; Simian adenovirus

Mesh:

Year:  2018        PMID: 30144567     DOI: 10.1016/j.meegid.2018.08.020

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  2 in total

1.  Genome Analyses of Ten New Ape Adenoviruses with Similarity to Human Mastadenovirus C.

Authors:  Selas T F Bots; Vera Kemp; Iris J C Dautzenberg; Rob C Hoeben
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

Review 2.  Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?

Authors:  Selas T F Bots; Rob C Hoeben
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.